NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.91 -0.66 (-0.85%) GOLD FUTURES
2,337.10 -55.80 (-2.33%) DOW
39,057.32 -613.72 (-1.55%) Bitcoin GBP
53,064.33 -1,727.54 (-3.15%)
Palisade Bio, Inc. (PALI)
| Previous close | 5.16 |
| Open | 5.01 |
| Bid | 3.88 x 200 |
| Ask | 6.41 x 200 |
| Day's range | 5.01 - 5.52 |
| 52-week range | 3.82 - 36.60 |
| Volume | |
| Avg. volume | 1,138,378 |
| Market cap | 4.782M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patients Company on track to commence Phase 1 human clinic
- GlobeNewswire
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and reach clinical and regulatory milestones into 2025 Carlsbad, CA, May 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living w
- GlobeNewswire
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Palisade Bio, Inc. Margery Fischbein Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announ
